0823 GMT - The pace of Haleon's transformation is slow, as there isn't sufficient portfolio resilience, Barclays analyst Warren Ackerman says in a note. The U.K. consumer-healthcare company has a strong portfolio of brands, like Advil and Panadol, but its execution has been disappointing, he says. "More progress should have been made," the analyst writes.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments